FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W84085943> ?p ?o ?g. }

• W84085943 endingPage "276" @default.
• W84085943 startingPage "270" @default.
• W84085943 abstract "Rheumatoid arthritis (RA) is a proven high cardiovascular risk disease. High heart rate (HR), lower heart rate variabil- ity (HRV), and increased QT interval are considered as predictors of cardiovascular events in patients with coronary heart disease, chronic heart failure, and diabetes mellitus. In RA, there is a pronounced rise in HR, a reduction in HRV, and an increase in QT interval mainly due to the factors reflecting the severity of the disease. Rituximab (RTM) is successfully used to treat patients with high RA activity. At the same time there are only a few pieces of evidence for the effect of the drug on the cardiovascular system. Objective: to study changes in HR, HRV, and QT interval values obtained during electrocardiography (ECG) Holter monitoring (ECG HM) in RTM-treated women during a 6-month follow-up. Subjects and methods: The investigation enrolled 55 women (mean age 50 years) with a definite diagnosis of RA and its high activity. The patients were examined 6 months after administration of RTM. The latter was infused intra- venously twice (500 and 1000 mg in 22% and 78% of the patients, respectively) during therapy with disease-modifying antirheumatic and non-steroidal anti-inflammatory drugs and glucocorticoids. The RA patients were divided into two groups: 1) a satisfactory/good effect of RTM according to the EULAR criteria (n = 41); 2) no effect (n = 14). Analysis of 24-hour ECG HM yielded the values of HR and mean duration of corrected QT interval (QTc). The tim- ing HRV values obtained at ECG HM were standardized from age and mean HR (SDNNn, RMSSDn, and pNN50n). Results. The baseline HRmin and HRmean values were higher and SDNNn was lower in the RA patients in Group 1 than those in Group 2 (p < 0.05). In Group 1, RTM therapy was accompanied by a reduction in HRmean and HRmin  by 8% and by an increase in SDNNn by 3%, RMSSDn by 26%, and pNN50n by 33% whereas no significant changes in HR and HRV were found in Group 2. The RTM therapy-induced HRmean decrease was associated with the reductions of C-reactive protein concentration and HAQ disability index (p < 0.01), the increases of rMSSDn and pNN50n associated with lower HAQ index, ERS, and DAS28 (p < 0.01). There were no differences in QTc in Groups 1 and 2 during 6 months after RTM therapy. Thus, effective RTM therapy is attended by reduced HR and improved HRV values." @default.
• W84085943 created "2016-06-24" @default.
• W84085943 creator A5021074423 @default.
• W84085943 creator A5034649782 @default.
• W84085943 creator A5039229305 @default.
• W84085943 creator A5072240642 @default.
• W84085943 creator A5074646458 @default.
• W84085943 creator A5079352743 @default.
• W84085943 date "2014-06-20" @default.
• W84085943 modified "2023-09-25" @default.
• W84085943 title "Динамика частоты сердечных сокращений, показателей вариабельности ритма сердца и величины интервала Q–T у женщин с ревматоидным артритом на фоне лечения ритуксимабом" @default.
• W84085943 doi "https://doi.org/10.14412/1995-4484-2014-270-276" @default.
• W84085943 hasPublicationYear "2014" @default.
• W84085943 type Work @default.
• W84085943 sameAs 84085943 @default.
• W84085943 citedByCount "1" @default.
• W84085943 countsByYear W840859432016 @default.
• W84085943 crossrefType "journal-article" @default.
• W84085943 hasAuthorship W84085943A5021074423 @default.
• W84085943 hasAuthorship W84085943A5034649782 @default.
• W84085943 hasAuthorship W84085943A5039229305 @default.
• W84085943 hasAuthorship W84085943A5072240642 @default.
• W84085943 hasAuthorship W84085943A5074646458 @default.
• W84085943 hasAuthorship W84085943A5079352743 @default.
• W84085943 hasConcept C118441451 @default.
• W84085943 hasConcept C126322002 @default.
• W84085943 hasConcept C134018914 @default.
• W84085943 hasConcept C164705383 @default.
• W84085943 hasConcept C2777575956 @default.
• W84085943 hasConcept C2777953023 @default.
• W84085943 hasConcept C2778198053 @default.
• W84085943 hasConcept C2780040984 @default.
• W84085943 hasConcept C2780074459 @default.
• W84085943 hasConcept C555293320 @default.
• W84085943 hasConcept C71635504 @default.
• W84085943 hasConcept C71924100 @default.
• W84085943 hasConcept C84393581 @default.
• W84085943 hasConceptScore W84085943C118441451 @default.
• W84085943 hasConceptScore W84085943C126322002 @default.
• W84085943 hasConceptScore W84085943C134018914 @default.
• W84085943 hasConceptScore W84085943C164705383 @default.
• W84085943 hasConceptScore W84085943C2777575956 @default.
• W84085943 hasConceptScore W84085943C2777953023 @default.
• W84085943 hasConceptScore W84085943C2778198053 @default.
• W84085943 hasConceptScore W84085943C2780040984 @default.
• W84085943 hasConceptScore W84085943C2780074459 @default.
• W84085943 hasConceptScore W84085943C555293320 @default.
• W84085943 hasConceptScore W84085943C71635504 @default.
• W84085943 hasConceptScore W84085943C71924100 @default.
• W84085943 hasConceptScore W84085943C84393581 @default.
• W84085943 hasIssue "3" @default.
• W84085943 hasLocation W840859431 @default.
• W84085943 hasOpenAccess W84085943 @default.
• W84085943 hasPrimaryLocation W840859431 @default.
• W84085943 hasVolume "52" @default.
• W84085943 isParatext "false" @default.
• W84085943 isRetracted "false" @default.
• W84085943 magId "84085943" @default.
• W84085943 workType "article" @default.